Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?

被引：9

作者：

Andreea, Munteanu Madalina ^{[1
,2
]}

Surabhi, Swarnkar ^{[3
]}

Razvan-Ionut, Popescu ^{[2
,4
]}

Lucia, Ciobotaru ^{[5
]}

Camelia, Nicolae ^{[1
,2
]}

Emil, Tufanoiu ^{[6
,7
]}

Tiberiu, Nanea Ioan ^{[1
,2
]}

机构：

[1] Univ Med & Pharm Carol Davila, Dept Cardiol, Bucharest 050474, Romania

[2] Theodor Burghele Clin Hosp, Bucharest 050653, Romania

[3] Univ Med Ctr Gottingen, Dept Cardiovasc Sci, D-37075 Gottingen, Germany

[4] Univ Med & Pharm Carol Davila, Dept Urol, Bucharest 050474, Romania

[5] Univ Med & Pharm Carol Davila, Dept Nephrol, Bucharest 050474, Romania

[6] Univ Med & Pharm Carol Davila, Dept Neurol, Bucharest 050474, Romania

[7] Fundeni Clin Inst, Bucharest 022328, Romania

来源：

MEDICINA-LITHUANIA | 2023年 / 59卷 / 04期

关键词：

heart failure; SGLT2; inhibitors; type; 2; diabetes; cardiovascular effects; PRESERVED EJECTION FRACTION; HEART-FAILURE; DIABETES-MELLITUS; HEPATIC-FIBROSIS; DOUBLE-BLIND; RISK-FACTOR; EMPAGLIFLOZIN; SAFETY; DAPAGLIFLOZIN; ATHEROSCLEROSIS;

D O I：

10.3390/medicina59040742

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There is a need for innovative pharmaceutical intervention in light of the increasing prevalence of metabolic disease and cardiovascular disease. The kidneys' sodium-glucose cotransporter 2 inhibitors (SGLT2) receptors are targeted to reduce glucose reabsorption by SGLT2. Patients with type 2 diabetes mellitus (T2DM) benefit the most from reduced blood glucose levels, although this is just one of the numerous physiological consequences. To establish existing understanding and possible advantages and risks for SGLT2 inhibitors in clinical practice, this article will explore the influence of SGLT2 inhibitors on six major organ systems. In addition, this literature review will discuss the benefits and potential drawbacks of SGLT2 inhibitors on various organ systems and their potential application in therapeutic settings.

引用

页数：14

共 84 条

[1] Empagliflozin alleviates neuronal apoptosis induced by cerebral ischemia/reperfusion injury through HIF-1α/VEGF signaling pathway [J].

Abdel-latif, Rania G. ;

Rifaai, Rehab A. ;

Amin, Entesar F. .

ARCHIVES OF PHARMACAL RESEARCH, 2020, 43 (05) :514-525

[2] Potential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke [J].

Al Hamed, Fatima Alzahra ;

Elewa, Hazem .

CLINICAL THERAPEUTICS, 2020, 42 (11) :E242-E249

[3]

Ali A, 2019, DIABETES THER, V10, P1595, DOI 10.1007/s13300-019-0657-8

[4] Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Shahzeb Khan, Muhammad ;

Pedro Ferreira, Joao ;

Bocchi, Edimar ;

Bohm, Michael ;

Pieter Brunner-La Rocca, Hans ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure, Eduardo ;

Giannetti, Nadia ;

Esteban Gomez-Mesa, Juan ;

Janssens, Stefan ;

Januzzi, James L. ;

Gonzalez-Juanatey, Jose R. ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio, V ;

Pina, Ileana L. ;

Ponikowski, Piotr ;

Senni, Michele ;

Seronde, Marie-France ;

Sim, David ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Vinereanu, Dragos ;

Zhang, Jian ;

Jamal, Waheed ;

Schnaidt, Sven ;

Schnee, Janet M. ;

Brueckmann, Martina ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (12) :2383-2392

[5] Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong [J].

Au, Philip C. M. ;

Tan, Kathryn C. B. ;

Lam, David C. L. ;

Cheung, Bernard M. Y. ;

Wong, Ian C. K. ;

Kwok, Wang Chun ;

Sing, Chor-Wing ;

Cheung, Ching-Lung .

JAMA NETWORK OPEN, 2023, 6 (01) :e2251177

[6] Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study [J].

Bilgin, Satilmis ;

Kurtkulagi, Ozge ;

Duman, Tuba Taslamacioglu ;

Tel, Burcin Meryem Atak ;

Kahveci, Gizem ;

Kiran, Murat ;

Erge, Eray ;

Aktas, Gulali .

IRISH JOURNAL OF MEDICAL SCIENCE, 2022, 191 (04) :1647-1652

[7] Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion [J].

Bonner, Caroline ;

Kerr-Conte, Julie ;

Gmyr, Valery ;

Queniat, Gurvan ;

Moerman, Ericka ;

Thevenet, Julien ;

Beaucamps, Cedric ;

Delalleau, Nathalie ;

Popescu, Iuliana ;

Malaisse, Willy J. ;

Sener, Abdullah ;

Deprez, Benoit ;

Abderrahmani, Amar ;

Staels, Bart ;

Pattou, Francois .

NATURE MEDICINE, 2015, 21 (05) :512-U139

[8] Patterns and Patients' Characteristics Associated With Use of Sodium-Glucose Cotransporter-2 Inhibitors Among Adults With Type 2 Diabetes: A Population-based Cohort Study [J].

Campbell, Dennis B. ;

Campbell, David J. T. ;

Au, Flora ;

Beall, Reed F. ;

Ronksley, Paul E. ;

Chew, Derek S. ;

Ogundeji, Yewande ;

Manns, Braden J. ;

Hemmelgarn, Brenda R. ;

Tonelli, Marcello ;

Quinn, Amity E. .

CANADIAN JOURNAL OF DIABETES, 2023, 47 (01) :58-+

[9] SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug? [J].

Chan, Jonathan C. H. ;

Chan, Michael C. Y. .

MEDICINA-LITHUANIA, 2023, 59 (02)

[10] Efficacy and safety of combination therapy with SGLT2 and DPP4 inhibitors in the treatment of type 2 diabetes: A systematic review and meta-analysis [J].

Cho, Y. K. ;

Kang, Y. M. ;

Lee, S. E. ;

Lee, J. ;

Park, J. -Y. ;

Lee, W. J. ;

Kim, Y. -J. ;

Jung, C. H. .

DIABETES & METABOLISM, 2018, 44 (05) :393-401

← 1 2 3 4 5 6 7 8 9 →